Special Issue "Pancreatic Ductal Adenocarcinoma: From Pathophysiology to Novel Therapeutic Approaches"
A special issue of Biomedicines (ISSN 2227-9059).
Deadline for manuscript submissions: 30 June 2020.
Interests: pathology; oncology; molecular biomarkers; tumor molecular profiling; immunohistochemistry; prognosis; survival; metastatic relapse; targeted therapy; pancreatic adenocarcinoma; breast cancer; bladder cancer; colorectal cancer; lung cancer; prostate cancer; GBM; paraganglioma; thymic epithelial tumors; melanoma; pulmonary carcinoid; signal transduction; epigenetics; angiogenesis; extracellular matrix; epidermal growth factor receptors; antibody drug conjugate (ADC)
Pancreatic cancer (PC) is one of the leading causes of cancer-related death worldwide. The dismal prognosis of PC patients is attributable to the strong propensity of the disease to disseminate at an early stage. Thus, at the time of diagnosis, only 20% of PC patients are eligible for surgical resection. Furthermore, resistance to chemotherapy and radiotherapy contributes to the high mortality rates registered in PC patients. Hence, there is an urgent need to find new therapeutic strategies that can be more specific and more effective for treatment of PC patients. This Special Issue will provide insights regarding the molecular pathogenesis of PC and how the molecular driver of PC cells could be targeted. Authors are invited to submit their original research, communications, and review articles to Biomedicines.
Potential topics include but are not limited to:
- The role of cancer stem cells or tumor-initiating cells in the genesis and progression of PC;
- Genetic changes and gene expression patterns associated with PC subtypes;
- The impact of the epigenetic changes in PC;
- The contribution of tumor stroma in the PC;
- Potential biomarkers for predicting the progression and response to therapy of PC;
- The immuno-oncology approaches in PC;
- Antistroma therapies in PC;
- Role of the exosomes in PC.
Dr. Rossano Lattanzio
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- pancreatic ductal adenocarcinoma
- targeted therapy
- drug resistance
- molecular profiling
The below list represents only planned manuscripts. Some of these manuscripts have not been received by the Editorial Office yet. Papers submitted to MDPI journals are subject to peer-review.
Title: Biomarkers and Targeted Therapy in pancreatic cancer
Authors: Jong Kook Park, etc.
Title: Mitochondrial metabolism in PDAC: from better knowledge to new targeting strategies".
Authors: Alice Carrier, etc.
Title: Targeting mutant KRAS in pancreatic cancer: futile or promising?
Authors: Dietrich A. Ruess, etc.
Title: Pancreatic cancer: molecular drivers and role of targeted therapy
Authors: Bayan AlShare, etc.
Title: Roles of the drug transporter ABCC3 and the orphan G protein-coupled receptor GPR55 in pancreatic cancer chemoresistance
Authors: Rossano Lattanzio, etc.
Title: Defining parallels between the salivary glands and pancreas to better understand pancreatic carcinogenesis
Author: Céline Tiffon
Title: The interplay between the pancreatic tumor microenvironment and cancer invasion
Authors: Begona Diaz, etc.